An interventional study of DERA Online Training Program in Alzheimer's Disease and Related Dementia, sponsored by George Mason University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by George Mason University · Not applicable, Interventional, and Other
The goal of this intervention trial is to evaluate the effectiveness the online training program Dementia Education and Resources for Action (DERA) in improving Alzheimer's disease and related dementia-(ADRD) knowledge, stigma, and service-related self-efficacy among community health workers (CHWs). We hypothesize that participants who have completed the DERA will have improved ADRD knowledge and self-efficacy in related service and reduced stigma against ADRD and people affected.
3,965 studies on the registry are indexed under Alzheimer Disease; 926 are open to participants now.
This study's planned enrollment of 100 is above the median of 70 across 3,019 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →George Mason University is the lead sponsor of 43 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this arm will receive immediate access to the DERA online training program. The program is web-based platform and includes 7 structured modules on dementia knowledge, stigma reduction, and the role of community health workers in supporting individuals with dementia and their caregivers.
Behavioral: DERA Online Training Program
Participants assigned to this arm will not receive access to the DERA program during the study period. They will complete baseline and post-intervention assessments over a similar timeframe as the intervention group. After completion of the post-intervention assessment, participants will be provided access to the DERA training program.
The Dementia Education and Resources for Action (DERA) program is a structured, online training intervention designed for community health workers. The program consists of approximately 7 sessions delivered through a web-based platform. Content includes dementia fundamentals, early signs and risk factors, stigma reduction, and strategies for communication, support, and service navigation. The training incorporates video-based instruction, interactive materials, and quizzes to support learning and engagement.
Dementia Knowledge
Dementia knowledge will be assessed using the Dementia Knowledge Assessment Scale (DKAS). The DKAS is a validated instrument that measures knowledge across multiple domains, including causes, symptoms, risk factors, and care considerations. DKAS-25 total score ranges from 0 to 50. Items are scored 0-2, with higher scores indicating greater dementia-related knowledge.
Time frame: Baseline to post-intervention (approximately 6-8 weeks)
Dementia-Related Stigma
Dementia-related stigma will be assessed using an adapted 8-item stigma scale with response options ranging from strongly disagree to strongly agree. Total scores range from 8 to 40, with higher scores indicating greater dementia-related stigma.
Time frame: Baseline to post-intervention (approximately 6-8 weeks)
Self-Efficacy in Dementia Care
Self-efficacy will be measured using a study-specific Community Health Worker Dementia Role Self-Efficacy Scale assessing confidence in performing dementia-related tasks, including education, communication, support, and service navigation. Response options range from "Not at all confident" to "Extremely confident." Total scores range from 8 to 40, with higher scores indicating greater self-efficacy in dementia-related service delivery.
Time frame: Baseline to post-intervention (approximately 6-8 weeks)
Plan to share: No — Individual participant data will not be publicly shared due to privacy considerations. De-identified data may be made available upon reasonable request to the study investigators, subject to institutional review and data use agreements.
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.
Of 882 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 6 months is below that.
Counting every sponsor, half of 959 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
George Mason University